Trevi Therapeutics (NASDAQ:TRVI) Earns "Sell (D-)" Rating from Weiss Ratings

Key Points

• Weiss Ratings has restated Trevi Therapeutics' stock rating as "Sell (D-)", indicating a negative outlook on the investment.
• The stock has a consensus rating of "Moderate Buy" among analysts, with a price target averaging around $21.75, though several firms have adjusted their price objectives downward.
• Shares of Trevi Therapeutics rose 2.8% to $9.82, reflecting some trading activity despite a negative overall sentiment from analysts.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Other analysts also recently issued research reports about the stock. Raymond James Financial decreased their price objective on shares of Trevi Therapeutics from $29.00 to $27.00 and set a "strong-buy" rating on the stock in a report on Friday, August 8th. Morgan Stanley began coverage on shares of Trevi Therapeutics in a report on Thursday, August 21st. They set an "overweight" rating and a $18.00 price objective on the stock. Needham & Company LLC decreased their price objective on shares of Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Finally, Cantor Fitzgerald began coverage on shares of Trevi Therapeutics in a report on Tuesday, July 1st. They set an "overweight" rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $21.75.

Trevi Therapeutics Trading Up 2.8%

Shares of NASDAQ:TRVI traded up $0.27 during midday trading on Wednesday, hitting $9.82. The stock had a trading volume of 1,215,189 shares, compared to its average volume of 2,597,842. The company has a market capitalization of $1.20 billion, a PE ratio of -23.38 and a beta of 0.74. The stock has a 50 day moving average price of $8.05 and a two-hundred day moving average price of $6.93. Trevi Therapeutics has a 1 year low of $2.36 and a 1 year high of $10.16.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. As a group, equities analysts expect that Trevi Therapeutics will post -0.49 EPS for the current year.

Hedge Funds Weigh In On Trevi Therapeutics

A number of institutional investors have recently modified their holdings of the company. Persistent Asset Partners Ltd raised its position in shares of Trevi Therapeutics by 3.3% in the second quarter. Persistent Asset Partners Ltd now owns 42,788 shares of the company's stock valued at $234,000 after buying an additional 1,384 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Trevi Therapeutics by 10.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 17,925 shares of the company's stock valued at $113,000 after purchasing an additional 1,627 shares during the period. American Century Companies Inc. grew its holdings in Trevi Therapeutics by 2.1% in the first quarter. American Century Companies Inc. now owns 79,796 shares of the company's stock valued at $502,000 after purchasing an additional 1,653 shares during the period. Steward Partners Investment Advisory LLC grew its holdings in Trevi Therapeutics by 20.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 12,000 shares of the company's stock valued at $66,000 after purchasing an additional 2,000 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in Trevi Therapeutics by 194.5% in the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company's stock valued at $25,000 after purchasing an additional 2,996 shares during the period. Institutional investors and hedge funds own 95.76% of the company's stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.